Apollomics (APLM) Beginning Cash Balance (2021 - 2022)
Apollomics' (APLM) quarterly Beginning Cash Balance came in at $32.9 million in Q4 2022, down 55.36% year-over-year from $73.6 million in Q4 2021, and down 55.36% quarter-over-quarter from $73.6 million in Q4 2021.
Powered by 
Analysis
Apollomics (APLM) Beginning Cash Balance (2021 - 2022) Analysis & Trends
Apollomics (APLM) has reported Beginning Cash Balance for 2 consecutive years, with $32.9 million the latest figure, recorded in Q4 2022.
- On a quarterly basis, Beginning Cash Balance fell 55.36% year-over-year to $32.9 million in Q4 2022; TTM through Dec 2022 was $32.9 million, a 55.36% decrease from a year earlier, with the FY2022 full-year figure at $32.9 million, down 55.36% from the prior year.
- Beginning Cash Balance was $32.9 million for Q4 2022 at Apollomics, down from $73.6 million in the prior quarter.
- Over five years, Beginning Cash Balance peaked at $73.6 million in Q4 2021 and troughed at $32.9 million in Q4 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Apollomics | 34.50 Mn | 31.23 Mn | - |